Evidence map›Paper›PMID 41578380›Full record

ArticleEuropean journal of medical research2026

COLEC10 and COLEC11 are new serum biomarkers of chronic liver disease.

Tongguo Yang, Yang Jing, Kun Li, Manzhou Wang, Shuguang Ju, Zhe Zhou, Xiaocang Cao, Mengfan Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tongguo Yang *Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No.1 East Jianshe Road, Zhengzhou, 450052, Henan, China.
Yang Jing *Department of Hepato-Gastroenterology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China.
Kun LiDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No.1 East Jianshe Road, Zhengzhou, 450052, Henan, China.
Manzhou WangDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No.1 East Jianshe Road, Zhengzhou, 450052, Henan, China.
Shuguang JuDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No.1 East Jianshe Road, Zhengzhou, 450052, Henan, China.
Zhe ZhouDepartment of Nutrition, Tianjin Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, Tianjin, China.
Xiaocang CaoDepartment of Hepato-Gastroenterology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China.
Mengfan ZhangDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No.1 East Jianshe Road, Zhengzhou, 450052, Henan, China. mengfanzhang@zzu.edu.cn.

Funding

the Department of Science and Technology of Henan Province 24B320022the Health Commission of Henan Province LHGJ20210287
6 · The paper itself

Abstract

backgroundCOLEC10 and COLEC11 are presumed to act as pattern recognition receptors to activate the complement system by binding to MASP1. However, it is not clear whether the serum concentrations of COLEC10, COLEC11 and MASP1 can be diagnostic markers of chronic liver disease (CLD).

aimsThis study aimed to investigate the diagnostic value of serum concentrations of COLEC10, COLEC11 and MASP1 in CLD.

methodsThe study included 17 healthy donors and 128 patients who were diagnosed with chronic liver disease. The serum concentrations of COLEC10, COLEC11 and MASP1 were measured with ELISA kits. The clinical data of the patients were collected and analyzed.

resultsThe serum concentrations of COLEC10 and COLEC11 are significantly increased in the patients with CLD. However, the serum concentration of MASP1 did not show a significant change in patients with CLD. The univariate correlation analysis reveals that the serum concentrations of COLEC10, COLEC11 and MASP1 are not strongly correlated with other clinical markers. Subgroup analysis based on the etiology of chronic liver disease demonstrates that the serum concentrations of COLEC10 and COLEC11 are increased in patients with viral hepatitis, autoimmune hepatitis, and alcoholic hepatitis, but not in metabolic dysfunction-associated steatotic liver disease, whereas MASP1 is only increased in patients with alcoholic hepatitis. The serum concentrations of COLEC10, COLEC11 and MASP1 are increased in patients with liver cirrhosis.

conclusionsThis study demonstrates that the serum concentrations of COLEC10 and COLEC11 are new biomarkers of chronic liver disease characterized by liver fibrosis and an advanced-stage phenotype. Further studies are needed to confirm the clinical value of serum concentrations of COLEC10 and COLEC11 in the diagnosis and prognosis of chronic liver disease.

Indexed as

Chronic liver diseaseCollectinHepatic stellate cellLectinSerum marker

Identifiers

PMID41578380
PMCPMC12911374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.